Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLR1 | P15328 | 1/20 | 0.44 |
| ▸ | GART | P22102 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.31 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.31 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.31 |
| ▸ | GGH | Q92820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609290 | 0.76 | GART (0.79) | FOLR1GART | |
| SCHEMBL7739887 | 0.60 | NAALAD2 (0.46) | HPGDFOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL60370 | 0.57 | GAA (0.62) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL60371 | 0.57 | GAA (0.62) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL7164156 | 0.57 | NAALAD2 (0.36) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL25329657 | 0.56 | APEX1 (0.43) | KDM4EFOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL10935609 | 0.56 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL14722083 | 0.56 | FOLH1 (0.56) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL10935612 | 0.56 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL6427494 | 0.56 | FOLH1 (0.64) | KDM4EHPGDFOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010018443-A1 | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | VARNEY MICHAEL D (US) | 2001-08-30 | — | — | US | disclosed |
| EP-0674516-B1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMA (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0674516-A4 | — | — | 1995-10-25 | — | — | EP | disclosed |
| EP-0674516-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994013295-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018443-A1 | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | GART, GARS1, NUDT1 | FOLR1 586/4885GART 1/4885TBXAS1 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.